Company intelligence / Profile preview
Eximore
Israeleximore.co.il ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
The company is developing a non-invasive punctal plug drug delivery system that addresses the challenges of eye drops while leveraging the high retention, tolerability, and safety of conventional punctal plugs using nano-particle technology to mold drugs into the actual plug itself.
- Therapeutic areas
- Ophthalmology
- Modalities
- Drug-eluting punctal plugsnano-particle technology
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Eximore.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eximore.